Current Report Filing (8-k)
November 30 2015 - 4:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
November 23, 2015
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware |
000-51038 |
98-0373793 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(I.R.S. Employer
Identification No.) |
7 Deer Park Drive, Suite K,
Monmouth Junction, New Jersey |
08852 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (732) 329-8885
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| ¨ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On November 13, 2015, CytoSorbents Corporation (the “Company”), announced that it had submitted an Expedited Access
Pathway (“EAP”) application to the U.S. Food and Drug Administration (the “FDA”) to request EAP
designation status for treatment of sepsis with the Company’s CytoSorb® device. EAP designation is equivalent to “Breakthrough”
designation for drugs and biologics, but designed for medical devices that address major unmet medical needs.
On November 23, 2015, the FDA
notified the Company that additional data were necessary to be eligible for EAP designation status consideration. The Company
has engaged with the FDA and is currently in the process of scheduling a teleconference to discuss the amount and type of
data required in greater detail. Although the Company is confident that additional data are available, there can be no
assurances that such data are sufficient to obtain EAP designation for CytoSorb to treat sepsis at this time. In the event
the Company does not receive EAP designation status for CytoSorb at this time, the Company plans to seek feedback from the
FDA on its draft data development plan and clinical trial design during the pre-submission
review process in preparation of either resubmitting an EAP application when the appropriate data are available,
or filing an investigational device exemption (“IDE”)
to conduct a sepsis study in the United States towards a pre-market approval (“PMA”)
pathway.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 30, 2015 |
CYTOSORBENTS CORPORATION |
|
|
|
|
By: |
/s/ Dr. Phillip P. Chan |
|
Name: |
Dr. Phillip P. Chan |
|
Title: |
President and
Chief Executive Officer |
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Sep 2023 to Sep 2024